|Day Low/High||10.30 / 10.55|
|52 Wk Low/High||5.90 / 13.18|
The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 387,607 share decrease in total short interest for Cytokinetics Inc , to 3,108,691, a decrease of 11.09% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Discovery of Novel Binding Mechanism Has Potential to Guide Design of Myosin Inhibitors
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, ARLP, BHI, CYTK, MET, MGI, OSB, PBFX, SGEN, SPKE Downgrades: APO, CBL, CTS, FORM, ILG, NKSH, SPCB, TRS, TUES Initiations: CSWI Read on to get TheStreet Quant Ratings' detailed report:
Investors in Cytokinetics Inc saw new options begin trading this week, for the May 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 200 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Eligible Patients Have Completed Participation in Phase 3 Clinical Trial VITALITY-ALS
Investors eyeing a purchase of Cytokinetics Inc shares, but cautious about paying the going market price of $9.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $7 strike, which has a bid at the time of this writing of 55 cents.
Clearance Triggers $65 Million Upfront Cash Payment in Addition to $30 Million in Sponsored Research & Development Funding Through 2017
The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,457,024 share decrease in total short interest for Cytokinetics Inc , to 3,640,233, a decrease of 28.58% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Data Show Treatment with Omecamtiv Mecarbil May Improve Patient Symptoms at 20 Weeks
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Cytokinetics (CYTK) announced Thursday that its cardiac myosin activator drug has been advanced to phase III clinical development.
Company Expects the Initiation of Phase 3 Cardiovascular Outcomes Clinical Trial in Q4 2016
Results Expected 2H 2017; Open-Label Extension Trial to Begin in Q4 2016
Trade-Ideas LLC identified Cytokinetics (CYTK) as a strong on high relative volume candidate